Scienture Holdings (SCNX) Company Report

Scienture Holdings, Inc. announced the issuance of U.S. Patent No. 12,514,854 B2 for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February 5, 2041.
This Orange Book-listable patent strengthens the intellectual property supporting REZENOPY™, for which Scienture, LLC secured exclusive U.S. commercialization rights in March 2025.
REZENOPY™, the highest dosage naloxone HCl nasal spray approved by the FDA on April 19, 2024, targets the U.S. naloxone market, which had approximately $154 million in annual sales and 9.3 million units as of September 2025.

Jan 14, 2026, 1:05 PM

Scienture Holdings Provides Update on REZENOPY® Commercial Launch

SCNX

Product Launch

New Projects/Investments

Scienture Holdings provided an update on the commercial launch of REZENOPY®, a 10 mg naloxone HCl nasal spray approved by the FDA on April 19, 2024.
The U.S. naloxone market, as of September 2025, has approximately $154 million in annual sales and 9.3 million units annually.
Manufacturing of REZENOPY® is on track, with product expected to be ready in Q1 2026, wholesale channel loading during Q1 2026, and commercial availability beginning in early Q2 2026.
REZENOPY® is positioned as the highest-strength naloxone available on the market, designed to support opioid receptor antagonism and address overdose situations involving multiple or potent opioids.

Dec 22, 2025, 1:05 PM

Scienture Holdings and BlinkRx Announce Strategic Collaboration for Arbli™ Access

SCNX

Product Launch

New Projects/Investments

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) and Blink Rx LLC announced a strategic collaboration to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium.
Arbli™ is expected to be available on the BlinkRx platform in Q1 2026.
The U.S. losartan market totals approximately $245 million in annual sales with over 71 million prescriptions annually, according to IQVIA data (MAT September 2025).
This partnership aims to improve patient access and adherence, with BlinkRx's platform historically leading to 52% more patients starting therapy and remaining on medication 40% longer.

Dec 10, 2025, 1:05 PM

Scienture Holdings, Inc. Secures New Debt and Repays Existing Loan

SCNX

Debt Issuance

Debt Repayment

On October 14, 2025, Scienture Holdings, Inc. issued a senior secured promissory note with a principal amount of $3,911,111.11 to Streeterville Capital, LLC, receiving net proceeds of $3,500,000 after an original issue discount and transaction expenses.
The new note carries an interest rate of 9% per annum and is due seven months from its issuance date.
The company used the net proceeds from the new note to fully repay all amounts due under its previous loan with NVK Finance LLC as of October 15, 2025.
Prior to repayment, the NVK Loan had an outstanding balance of $2,656,250 as of September 30, 2025, and its maturity date was extended to December 8, 2025, in exchange for a $25,000 amendment fee, a $25,000 maturity extension fee, and the issuance of 250,000 shares of common stock to NVK.